BMY.SW CHF42.54 down 4.40% after hours 03 Feb 2026: earnings due Feb 05 could shift stock

BMY.SW stock opened the after-hours session at CHF42.54, down 4.40% on heavy relative flow after the SIX close on 03 Feb 2026. The move arrives with Bristol-Myers Squibb (BMY.SW) set to report results on 05 Feb 2026, making the next two sessions critical for guidance. Key metrics: EPS CHF2.33, PE 18.26, 50/200-day average CHF43.75. Traders should watch earnings guidance, US market reaction, and short-term liquidity around the CHF42.50 level as catalysts for further price action.

BMY.SW stock: quick market snapshot

Bristol-Myers Squibb (BMY.SW) trades on the SIX in Switzerland at CHF42.54, after a -1.96 CHF intraday change and -4.40% decline. Volume shows 500 shares vs average 22, giving a relative volume of 22.73, a sign dealers moved size into the close. Year range sits between CHF42.54 and CHF44.75, and market cap reads CHF70,703,584,54.00 in the feed.

Earnings preview and near-term catalysts

Earnings are due 05 Feb 2026, and BMY.SW stock will react to sales guidance, margin commentary, and pipeline updates for oncology and cardiovascular franchises. Analysts will focus on guidance for Eliquis and immuno-oncology sales plus any commentary on generic pressure for legacy drugs. Ahead of the print, the market has discounted a conservative view, which helps explain today’s after-hours weakness.

Financials and valuation snapshot

Bristol-Myers shows EPS CHF2.33 and a trailing PE of 18.26 versus the healthcare sector average PE 34.55, indicating a valuation discount to peers. Key ratios: dividend yield 3.50%, debt/equity 2.92, free cash flow yield 14.52%, and price to sales 1.79. These metrics highlight solid cash generation but elevated leverage versus typical pharma peers.

Technicals, trading flow and sector context

Price sits below the 50/200-day averages (CHF43.75), signalling short-term weakness; the immediate support is CHF42.54 (today’s low) and resistance near CHF44.50 (previous close). Healthcare sector performance has been stronger YTD, with peers trading richer; BMY.SW’s relative weakness today increases sensitivity to the upcoming earnings print and US market sentiment.

Meyka AI rates BMY.SW with a score out of 100 and model forecasts

Meyka AI rates BMY.SW with a score out of 100: 67.54 (Grade B, suggestion HOLD). This grade factors in S&P 500 and sector comparison, financial growth, key metrics, and analyst signals. Meyka AI’s forecast model projects a 12-month target CHF48.40, a +13.78% implied upside from CHF42.54, a 3-year target CHF44.75 (+5.19%) and a 5-year target CHF41.24 (-3.06%). Forecasts are model-based projections and not guarantees.

Risks, watchlist and trading strategy

Key risks include weaker-than-expected earnings guidance, pipeline setbacks, generic erosion on legacy drugs, and a high debt load that limits flexibility. For traders, use earnings as a binary event: consider defined-risk positions ahead of the print or wait for guidance and a post-earnings setup. Long-term investors should weigh cash flow strength and dividend yield against leverage and modest EPS growth trends.

Final Thoughts

BMY.SW stock opened after hours at CHF42.54, dropping 4.40% into the SIX close on 03 Feb 2026, with the market now pricing in cautious near-term earnings risk ahead of the 05 Feb 2026 report. Valuation metrics show a discount to healthcare peers on PE but reflect higher leverage and an elevated payout ratio. Meyka AI’s model gives a 12-month target CHF48.40 (implied +13.78%) while also showing a flatter multi-year path, underlining event risk and modest upside. Investors should watch the earnings release for updated guidance, cash flow outlook, and commentary on key franchises such as Eliquis and oncology assets. For active traders, the next 72 hours offer an earnings-driven volatility window; longer-term holders should weigh the 3.50% dividend yield and free cash flow strength against debt metrics and sector multiples. Meyka AI, an AI-powered market analysis platform, provides these graded forecasts as model outputs and not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.